Los puntos clave no están disponibles para este artículo en este momento.
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).
Shaw et al. (Sat,) studied this question.